Mangoceuticals, Inc. has made significant changes to its capital structure by amending its preferred stock designations. The company introduced a new Series D Preferred Stock, which will rank senior to its common stock regarding dividends and liquidation preferences. This strategic move is expected to enhance the company's financial flexibility and could impact its future funding strategies.

The amendments were filed with the Texas Secretary of State and took effect on November 9, 2026. The changes were approved by the Board of Directors on November 4, 2026, following a written consent from the Series B Preferred Stockholders on November 2, 2026. This indicates a proactive approach by Mangoceuticals to strengthen its capital base and ensure it can meet future financial obligations.

Background

Mangoceuticals, Inc. operates in the health services sector, specifically classified under the SIC code 8090, which encompasses services related to miscellaneous health and allied services. The company is publicly traded on the Nasdaq under the ticker symbol MGRX. As an emerging growth company, Mangoceuticals is focused on expanding its operations and enhancing shareholder value through strategic financial maneuvers.

What the Filing Says

The recent filing outlines the amendments to the Series B and Series C preferred stock designations, which now include the Series D Preferred Stock. The filing states, "Upon issuance, the Series D Preferred Stock will rank senior to the Company’s registered common stock... with respect to dividends and distributions upon liquidation, dissolution or winding up." This establishes a clear hierarchy in the company's stock structure, prioritizing the Series D shares in financial distributions.

Impact

This restructuring may have significant implications for existing shareholders, particularly those holding Series B and Series C Preferred Stock. The new Series D shares will alter the dividend distribution landscape, potentially affecting the returns for common stockholders. Additionally, this move could influence investor sentiment and the company's attractiveness to future investors in the health services sector.

What's Next

The filing does not specify what happens next regarding the issuance of the Series D Preferred Stock or any further actions the company may take in response to these amendments.

For more details, the full filing can be accessed at the SEC's website under accession number 0001493152-26-051858.